WO2005097152A1 - Turmeric extract-containing composition having improved caking capacity - Google Patents

Turmeric extract-containing composition having improved caking capacity Download PDF

Info

Publication number
WO2005097152A1
WO2005097152A1 PCT/JP2005/005175 JP2005005175W WO2005097152A1 WO 2005097152 A1 WO2005097152 A1 WO 2005097152A1 JP 2005005175 W JP2005005175 W JP 2005005175W WO 2005097152 A1 WO2005097152 A1 WO 2005097152A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
fatty acid
lipophilic emulsifier
weight
mct
Prior art date
Application number
PCT/JP2005/005175
Other languages
French (fr)
Japanese (ja)
Inventor
Toshinori Ikehara
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Priority to JP2006511991A priority Critical patent/JPWO2005097152A1/en
Publication of WO2005097152A1 publication Critical patent/WO2005097152A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9066Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Definitions

  • composition containing konkon extract with improved caking properties Composition containing konkon extract with improved caking properties
  • the present invention relates to a composition containing a cocoon extract with improved caking properties, which facilitates the use of a cocoon extract having an effect of preventing or improving multiple 'risk' factor syndromes.
  • Ginger which is classified into the genus Gingidae (spring gong: Curcuma aromatica, autumn gong:
  • Curcuma longa is generally known as turmeric, one of the curry spices, and is widely used as food.
  • traditional therapies such as Chinese herbal medicine, Indian aurveda, and Indonesian jams have long been known to have haemostatic, stomach, antibacterial and anti-inflammatory effects. It's being used. Attention has also been paid to the effects of turmeric and its major component, curcumin, which have antioxidant effects, bile secretion promoting effects (biliary effects), visceral (liver, visceral) function enhancing effects, carcinogenesis suppressing effects, lipid metabolism improving effects, and whitening.
  • biliary effects bile secretion promoting effects
  • visceral liver, visceral
  • carcinogenesis suppressing effects lipid metabolism improving effects
  • whitening Various physiological actions such as actions have been elucidated.
  • konkon extract has an effect of preventing or improving the multiple risk factor syndrome such as visceral fat obesity, diabetes, hyperlipidemia and hypertension (International Publication No. 476 99 pamphlet), icon is an extremely
  • the konkon extract ( ⁇ konoleoresin) is curcumin and curcumin derivatives
  • Patent Document 1 WO 02/47699
  • Patent Document 2 JP-A-9-111282
  • Patent Document 3 JP 2001-86931A
  • Patent Document 4 JP-A-2003-137799
  • An object of the present invention relates to the use of a macaque extract having an extremely useful physiological action, and solves the problems of poor fluidity and adhesion to containers and the like by improving the above-mentioned undesirable properties.
  • Another object of the present invention is to provide a composition containing a high concentration of corn extract, which is extremely difficult to handle as it is.
  • the present inventors have conducted intensive studies and as a result, by mixing a cocoon extract with an edible oil / fat and / or a specific emulsifier, the caking property was remarkably improved, and the cocoon extract was improved The present inventors have found that a slurry having good fluidity can be obtained even if it is contained at a concentration, and have completed the present invention.
  • a first aspect of the present invention is that a lipophilic emulsifier containing a corn extract in an amount of more than 40% by weight, and having a medium chain fatty acid triglyceride and Z or fat and / or HLB value of 8.5 or less.
  • the present invention relates to a composition comprising a grape extract.
  • a preferred embodiment relates to the composition described above, characterized by comprising a medium-chain fatty acid triglyceride and a lipophilic emulsifier having a Z or HLB value of 8.5 or less.
  • the lipophilic emulsifier is a glycerin fatty acid ester, the composition containing a coconut extract described above, and further preferably, the lipophilic emulsifier is a polyglycerin fatty acid ester.
  • the corn extract extract-containing composition particularly preferably the corn extract extract-containing composition described above, wherein the constituent fatty acids of the polyglycerin fatty acid ester are unsaturated fatty acids, and very preferably the lipophilic emulsifier is diglycerin monoester.
  • the above-mentioned composition comprising a cocoon extract, which is an ester of oleic acid, and most preferably the effect of preventing or ameliorating multiple 'risk' factor syndrome. Extract-containing composition.
  • a second aspect of the present invention relates to a capsule enclosing the above-described composition.
  • a composition having a high viscosity and a low adherence to a container or the like can be provided despite containing a high concentration of a corn extract. Therefore, for example, it becomes easy to encapsulate the useful component of the cocoon in a soft capsule or the like at a high concentration.
  • the composition of the present invention has a very useful physiological activity, it has a high viscosity, a caking property, a poor fluidity and often adheres to a container.
  • a medium-concentrated triglyceride and / or fat and oil and a lipophilic emulsifier having a Z or HLB value of 8.5 or less with a high-concentration corn extract having a high concentration, the fluidity, adhesion and uniformity are excellent.
  • the composition containing the cocoon extract of the present invention has an advantage that it has an effect of preventing or ameliorating multiple 'risk' factor syndromes because it contains a high concentration of the cocoon extract.
  • a soft capsule containing a high-concentration cocoon extract can be used. It has the advantage that it can be easily manufactured.
  • the cocoon extract-containing composition of the present invention is obtained by mixing a cocoon extract with an oil component, which improves fluidity, and / or a lipophilic emulsifier, which improves cohesion.
  • the method for producing the icon extract of the present invention is not particularly limited, and it can be obtained by a conventionally known method, for example, a method of extracting the rhizome of the icon with warm ethanol. It is also possible to use commercially available Coneole Resin as it is.
  • the iconic extract used in the present invention includes curcumin, curcumin derivatives (eg, demethoxycurcumin, bisdemethoxycurcumin, dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, dihydroxytetracurcumin, etc.) and pisaborane-type
  • curcumin includes, for example, 1-bisabolene, ⁇ -curcumene, gingiberene, 1-sesquiferandrene, ar-turmerone, ⁇ -turmerone, and 3-turmerone.
  • the medium-chain fatty acid triglyceride (hereinafter also referred to as MCT) used in the present invention is a triglyceride having a fatty acid residue having 6 to 10 carbon atoms as a constituent fatty acid residue.
  • the fats and oils used in the present invention are edible fats and oils other than medium-chain fatty acid triglycerides, and are not particularly limited.
  • vegetable oils such as corn oil, rapeseed oil, high cinnamon rape oil, soybean oil, olive oil, safflower oil, cottonseed oil, castor oil, rice bran oil, palm oil, palm kernel oil, etc., fish oil, beef tallow, lard, milk fat, egg yolk
  • Animal oils such as oils, oils and fats which have been subjected to separation, hydrogenation, transesterification and the like using these as raw materials, or mixed oils thereof can be used.
  • the lipophilic emulsifier used in the present invention is not particularly limited as long as it can be uniformly mixed with the cocoon extract or the cocoon extract and fats and oils, but the HLB value is preferably 8.5 or less, more preferably 3 or less. —8.5, more preferably 5-8.5. This is because it is preferable that the solvent used for extracting the cocoon be closer to the lipophilicity.
  • the lipophilicity mentioned here means that it can be dissolved in fats and oils, and those that can be dissolved in MCT or general edible fats and oils are defined as lipophilic emulsifiers. When the HLB value exceeds 8.5, emulsifiers are separated from cocoon extract and oils and fats May be.
  • the HLB value is generally a measure of the degree of hydrophilicity and lipophilicity of an emulsifier, and the smaller the value, the stronger the lipophilicity.
  • the method for determining the HLB value is not particularly limited, but can be determined, for example, by the following formula (see Dani Gakushi Dictionary, Tokyo Kagaku Dojin, 1st edition, published on October 1, 1994).
  • emulsifiers include glycerin fatty acid esters such as monoglycerin fatty acid ester, monoglycerin fatty acid organic acid ester, polyglycerin fatty acid ester, polyglycerin condensed ricinoleate ester, sorbitan fatty acid esters, polysorbates, Sugar fatty acid esters, propylene glycol fatty acid esters, lecithin and the like can be mentioned, and at least one of them can be used in combination.
  • polyglycerin fatty acid esters and polyglycerin condensed ricinoleate are more preferable, since glycerin fatty acid esters are preferred because they can effectively improve the caking property.
  • the caking property as referred to in the present invention means a balance between fluidity, adhesion to a container, and uniformity of each component of a composition containing a cocoon extract. The better the above three properties, the better the caking property. Also means good
  • Examples of the polyglycerin fatty acid ester and the polyglycerin condensed ricinoleate include an average degree of polymerization of polyglycerin of 2 to 10. Further, examples of the polyglycerin fatty acid ester include those in which the constituent fatty acid is a fatty acid having 6 to 22 carbon atoms. Among them, the constituent fatty acid is preferably an unsaturated fatty acid.
  • diglycerin monooleate Tetraglycerin pentaoleate, hexaglycerin pentaoleate, pentaglycerin trioleate, decaglycerin pentaoleate, decaglycerin decaoleate, decaglycerin depot oleate, etc.
  • diglycerin monooleates Tetraglycerin pentaoleate, hexaglycerin pentaoleate, pentaglycerin trioleate, decaglycerin pentaoleate, decaglycerin decaoleate, decaglycerin depot oleate, etc.
  • diglycerin monooleates referred and more preferred are diglycerin monooleates.
  • the lipophilic emulsifier having an MCT, fat or HLB value of S8.5 or less at least one of them can be used as long as it can be uniformly mixed with a cocoon extract. ⁇ As the content of corn extract increases, lipophilic emulsifiers with MCT and Z or HLB values of 8.5 or less are preferred. A mixture of lipophilic emulsifiers having an MCT and HLB value of 8.5 or less is more preferred. MCT is known to have a lower viscosity than general fats and oils and an effect of suppressing body fat.It is a uniform and fine slurry compared to general fats and oils, and has a large effect of improving fluidity and uniformity. A lipophilic emulsifier having an HLB value of 8.5 or less has a large effect of improving adhesion.
  • the contents of the cocoon extract, the medium-chain fatty acid triglyceride and / or the fat and oil, and the lipophilic emulsifier having a Z or HLB value of 8.5 or less in the cocoon extract-containing composition will be described in detail.
  • the lipophilic emulsifier having a medium chain fatty acid triglyceride and / or fat and / or Z or HLB value of 8.5 or less includes MCT alone, fat and oil alone, lipophilic emulsifier alone having an HLB value of 5 or less, MCT and Combination of fats and oils, Combination of MCT and lipophilic emulsifier with HLB value of 5 or less, Combination of fats and oils with lipophilic emulsifier with HLB value of 8.5 or less, MCT and fat with HLB value of 8.5 or less Combined with a lipophilic emulsifier. These combinations can be appropriately selected depending on the content of the Japanese extract.
  • the lipophilic emulsifier having an MCT and / or fat and / or HLB value of 8.5 or less is 60% by weight or more. It is.
  • MCT alone, fat alone, lipophilic emulsifier alone, combined use of MCT and fat, combined use of MCT and lipophilic emulsifier, combined use of fat and oil with lipophilic emulsifier, combined use of MCT with fat and oil and lipophilic emulsifier Good combination of,
  • MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat or oil, a combination of MCT and a lipophilic emulsifier, a fat or oil MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat or oil, a combination of MCT and a lipophilic emulsifier, a fat or oil
  • the combined amount of MCT, lipophilic emulsifier, and MCT, fat and oil, and lipophilic emulsifier in any combination is more than 50% by weight and less than 60% by weight.
  • the weight ratio of fats and fats to lipophilic emulsifiers which is preferably used in combination with MCT or with lipophilic emulsifiers, is 99.9 / 0.1-0.1 / 99.9 is preferred, and more preferably 90/10-0.1 / 99.9. It is preferable to set the weight ratio of the lipophilic emulsifier to be high in order to increase the ratio of fats and oils when the priority is placed on the fluidity and to improve the adhesion.
  • the content of the cocoon extract is 50% by weight or more and less than 60% by weight
  • MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat, a combination of MCT and a lipophilic emulsifier, Combinations of fats and lipophilic emulsifiers, combined use of MCTs and fats and lipophilic emulsifiers, in any combination the total amount is more than 40% by weight and not more than 50% by weight. Since fats and oils alone may not sufficiently improve the caking properties, the combination of fats and oils with MCTs or the combination of fats and oils with a lipophilic emulsifier is preferred, and both fluidity and adhesion are greatly improved.
  • the weight ratio of the fat and oil to the lipophilic emulsifier is preferably 90Z10 0.1 / 99.9 force S, more preferably 75 / 25-0.1 / 99.9.
  • the emulsifier ratio is set in a range higher than the case where the content of the product derived from corn is more than 40 wt% and less than 50 wt%.
  • the weight ratio of oil and fat to MCT when using oil and fat together with MCT is preferably 90 / 10-0.1 / 99.9, more preferably 70 / 30-0.1 / 99.9, and even more preferably f.
  • the ratio is 50 / 50-0.1 / 99.9, and the MCT ratio is higher and the range is set as compared with the case where the content of konkon extract is more than 0% and less than 50% by weight. It is preferable to set the weight ratio of the lipophilic emulsifier to be higher in order to increase the ratio of fats and oils when the priority is given to the fluidity and to prioritize the improvement in adhesion.
  • the weight ratio of MCT to the lipophilic emulsifier is preferably 90/10 to 10/90. Within this range, both fluidity and adhesion are significantly improved.
  • the combination use of MCT and a lipophilic emulsifier when the content of the cocoon extract is 60% by weight or more, the combination use of MCT and a lipophilic emulsifier, the combination use of a fat and oil with a lipophilic emulsifier, and the combination use of MCT with a fat and oil and a lipophilic emulsifier are preferred.
  • the combined amount of MCT and lipophilic emulsifier is more preferable, and the total amount is less than 40% by weight.
  • the weight ratio of the MCT to the lipophilic emulsifier is not particularly limited, but is preferably 0.1 / 99.9 to 99.9 / 0.1, more preferably 10/90. 90/10, more preferably 25 / 75-75 / 25, and most preferably 40 / 60-60 / 40.
  • fluidity is prioritized, the ratio of fats and oils is increased to improve adhesion. If priority is given, it is preferable to set the weight ratio of the lipophilic emulsifier to be high.
  • the composition of the icon extract is preferably adjusted under heating conditions as needed, and more preferably at about 20-60 ° C.
  • a predetermined amount of a cocoon extract and a predetermined amount of fats and oils or Z or a lipophilic emulsifier may be uniformly mixed by stirring under a predetermined temperature heating condition, for example, a paddle mixer.
  • Homomixer, A homogenizer, a high-pressure homogenizer, a colloid minole, a bead mill, or the like can be used.
  • the composition containing the radish extract prepared by the above-described method is preferably in the form of a capsule for more effective ingestion than the power that can be added to food as it is.
  • Soft capsules, hard capsules, seamless capsules and the like can be used.
  • various vitamins such as vitamins A, C, D, and E, and a formulation base such as beeswax and the like may be further added to the icon extract composition according to the purpose.
  • licorice hydrophobic extract, clove extract, cinnamon extract, etc. which has the effect of preventing or ameliorating multiple 'risk' factor syndrome, or materials commonly used as foods, and food additives such as antioxidants May be added.
  • Flows out quickly
  • Flows out slowly
  • A Flows out slowly when heated to 40 ° C
  • X Almost flows out even when heated to 40 ° C
  • * Emulsifier even when stirred Is not uniform and cannot be evaluated in a separated state.
  • uniform and fine slurry state
  • uniform but granular slurry state
  • uniform when stirred, but solid-liquid separation in a short time when allowed to stand

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)

Abstract

Concerning the utilization of turmeric having extremely useful physiological functions, attempts are made to improve the unfavorable caking capacity (i.e., a tendency toward caking due to its high viscosity and oily nature) of a turmeric extract to thereby overcome problems such as the poor fluidity and stickiness to containers. Thus, a composition containing a turmeric extract, which is difficult in handling as such, at a high concentration is provided. Using this turmeric extract-containing composition characterized by containing more than 40% by weight of a turmeric extract and comprising a fat and/or a lipophilic emulsifier having an HLB of 8.5 or less, useful components of turmeric are packed at a high concentration into a soft capsule or the like.

Description

明 細 書  Specification
粘結性が改善されたゥコン抽出物含有組成物  Composition containing konkon extract with improved caking properties
技術分野  Technical field
[0001] 本発明は、マルチプル'リスク'ファクター症候群を予防又は改善する効果を有する ゥコン抽出物の利用を容易にした、粘結性が改善されたゥコン抽出物含有組成物に 関する。  TECHNICAL FIELD [0001] The present invention relates to a composition containing a cocoon extract with improved caking properties, which facilitates the use of a cocoon extract having an effect of preventing or improving multiple 'risk' factor syndromes.
背景技術  Background art
[0002] ショウガ科ゥコン属に分類されるゥコン(春ゥコン: Curcuma aromatica,秋ゥコン: [0002] Ginger, which is classified into the genus Gingidae (spring gong: Curcuma aromatica, autumn gong:
Curcuma longa)は、一般的にはカレースパイスの一つであるターメリックとして知られ ており、広く食用として利用されている。一方、中国の漢方、インドのァーュルヴエー ダ、インドネシアのジャム一等の伝統療法においては、止血作用、健胃作用、抗菌作 用、抗炎症作用があることが古くから知られており、薬用としても利用されている。また 、ゥコン及び主要成分クルクミンの効能が着目され、抗酸化作用、胆汁分泌促進作 用 (利胆作用)、内臓 (肝臓、勝臓)機能増強作用、発癌抑制作用、脂質代謝改善作 用、美白作用等様々な生理作用が明らかにされてきている。更には、ゥコン抽出物に 、内臓脂肪型肥満、糖尿病、高脂血症、高血圧症等のマルチプノレ 'リスク'ファクター 症候群を予防又は改善する効果を有することが知られている(国際公開第 02/476 99号パンフレット)、ゥコンは様々な機能を有する極めて有用な素材である。 Curcuma longa) is generally known as turmeric, one of the curry spices, and is widely used as food. On the other hand, traditional therapies such as Chinese herbal medicine, Indian aurveda, and Indonesian jams have long been known to have haemostatic, stomach, antibacterial and anti-inflammatory effects. It's being used. Attention has also been paid to the effects of turmeric and its major component, curcumin, which have antioxidant effects, bile secretion promoting effects (biliary effects), visceral (liver, visceral) function enhancing effects, carcinogenesis suppressing effects, lipid metabolism improving effects, and whitening. Various physiological actions such as actions have been elucidated. Furthermore, it is known that konkon extract has an effect of preventing or improving the multiple risk factor syndrome such as visceral fat obesity, diabetes, hyperlipidemia and hypertension (International Publication No. 476 99 pamphlet), icon is an extremely useful material having various functions.
[0003] しかしながらゥコン抽出物(ゥコンォレオレジン)は、クルクミン及びクルクミン誘導体  [0003] However, the konkon extract (ゥ konoleoresin) is curcumin and curcumin derivatives
(タルクミノイド)の他にピサボラン型セスキテルペン等のテルペン類を含有している為 、その性状は高粘度の油状で粘結性を呈し、流動性の悪さや容器等への付着の問 題からそのままでは極めて扱いにくぐ例えばソフトカプセル等へ封入することも極め て困難であった。し力、も、水ゃトリグリセリドに溶けにくぐ溶液にするにはアルコール ゃケトン系の有機溶媒を用いなければならない等、ゥコン抽出物の利用を困難にし 用途が制限されてきた。尚、前記の国際公開第 02/47699号パンフレットに於いて 、ゥコン抽出物を用いたソフトカプセルの記載(ゥコン抽出物 40重量部、ゴマ油 55重 量部、グリセリン脂肪酸エステル 5重量部)があるが、ゥコン抽出物の性状に関する記 載はなぐ配合されている乳化剤に関する詳細について具体的に言及もされておら ず、実際にグリセリン脂肪酸エステルとしてエマルジー MS (理研ビタミン株式会社製 、 HLB = 4. 3)を用いて粘結性を評価した所、ソフトカプセルを何とか実験室レベル では作れたが、工業的にはソフトカプセルを作るには実用的でない粘結性であった。 従って、本発明に対して何ら示唆を与えるものではないことは明らかである。 Since it contains terpenes such as pisaborane-type sesquiterpenes in addition to (talcuminoids), its properties are high-viscosity oil and exhibit caking properties, and it has no problem due to poor fluidity and adhesion to containers. In such cases, it was extremely difficult to enclose in soft capsules, for example. In addition, the use of corn extract has become difficult, and its use has been limited, for example, an alcohol-ketone organic solvent must be used to make the solution difficult to dissolve in water-triglyceride. In the pamphlet of WO02 / 47699, there is a description of a soft capsule using a coconut extract (40 parts by weight of konkon extract, 55 parts by weight of sesame oil, 5 parts by weight of glycerin fatty acid ester).記 Notes on properties of corn extract No specific mention was made of the details of the emulsifier incorporated in the product, and the caking properties were actually evaluated using Emulgy MS (manufactured by RIKEN Vitamin Co., HLB = 4.3) as a glycerin fatty acid ester. After that, soft capsules could be made at the laboratory level, but it was impractical to make soft capsules industrially. Therefore, it is clear that the present invention has no suggestion.
[0004] この様なゥコン抽出物を利用する際の問題点を解決する手段として、ゥコン抽出物 とッヱインの混合物が提案されている(特開平 9—111282)。この方法によれば、常 温で非粘結性の固体を得ることが可能であるが、ゥコン抽出物含量は 50%程度が限 界である。また、製造工程で含水エタノール等の有機溶剤を使用すること、及びその 溶液を乾燥する工程が必要であることから、その製品は高価とならざるを得ない。  [0004] As a means for solving such a problem in using the icon extract, a mixture of the icon extract and the wine has been proposed (JP-A-9-111282). According to this method, it is possible to obtain a non-caking solid at room temperature, but the content of strawberry extract is limited to about 50%. In addition, the use of an organic solvent such as hydrous ethanol in the production process and the step of drying the solution are necessary, so that the product must be expensive.
[0005] また、ゥコン粉末から食用油脂ゃジグリセリドによる抽出も提案されている(特開 200 1—86931、特開 2003— 137799)。この方法によれば、ゥコンの有効成分を含むォ ィルを得ることが可能であるが、その濃度は本発明のように高濃度ではなぐクノレクミ ンの濃度で僅か 1 %程度に過ぎず、十分な生理作用を得る為には該オイルを大量に 摂取することになり、実用的なものではなかった。  [0005] Further, extraction of edible oils and fats from sesame powder with diglycerides has also been proposed (JP-A-2001-86931, JP-A-2003-137799). According to this method, it is possible to obtain an oil containing the active ingredient of a cocoon, but its concentration is only about 1%, which is not as high as that of the present invention, and is only about 1%. In order to obtain a great physiological effect, a large amount of the oil must be taken, which is not practical.
特許文献 1:国際公開第 02/47699号  Patent Document 1: WO 02/47699
特許文献 2:特開平 9 - 111282号  Patent Document 2: JP-A-9-111282
特許文献 3 :特開 2001-86931号  Patent Document 3: JP 2001-86931A
特許文献 4 :特開 2003-137799号  Patent Document 4: JP-A-2003-137799
発明の開示  Disclosure of the invention
発明が解決しょうとする課題  Problems to be solved by the invention
[0006] 本発明の目的は、極めて有用な生理作用を有するゥコン抽出物の利用に関し、上 述の好ましくない性状を改善することで、流動性の悪さや容器等への付着の問題を 解決し、そのままでは極めて扱いにくいゥコン抽出物を高濃度に含有する組成物を 提供することにある。 [0006] An object of the present invention relates to the use of a macaque extract having an extremely useful physiological action, and solves the problems of poor fluidity and adhesion to containers and the like by improving the above-mentioned undesirable properties. Another object of the present invention is to provide a composition containing a high concentration of corn extract, which is extremely difficult to handle as it is.
課題を解決するための手段  Means for solving the problem
[0007] 上記実情に鑑み、本発明者らは鋭意研究の結果、ゥコン抽出物と食用油脂及び/ 又は特定の乳化剤を混合することにより粘結性が著しく改善され、ゥコン抽出物を高 濃度に含有しても良好な流動性を有するスラリーが得られることを見出し、本発明を 完成するに至った。 [0007] In view of the above-mentioned circumstances, the present inventors have conducted intensive studies and as a result, by mixing a cocoon extract with an edible oil / fat and / or a specific emulsifier, the caking property was remarkably improved, and the cocoon extract was improved The present inventors have found that a slurry having good fluidity can be obtained even if it is contained at a concentration, and have completed the present invention.
[0008] 即ち、本発明の第 1は、ゥコン抽出物を 40重量%を超えて含有し、且つ、中鎖脂肪 酸トリグリセリド及び Z又は油脂及び/又は HLB値が 8. 5以下の親油性乳化剤から なることを特徴とするゥコン抽出物含有組成物に関する。好ましい実施態様は、中鎖 脂肪酸トリグリセリド及び Z又は HLB値が 8. 5以下の親油性乳化剤からなることを特 徴とする上記記載のゥコン抽出物含有組成物に関する。より好ましくは、親油性乳化 剤がグリセリン脂肪酸エステルであることを特徴とする上記記載のゥコン抽出物含有 組成物、更に好ましくは親油性乳化剤がポリグリセリン脂肪酸エステルであることを特 徴とする上記記載のゥコン抽出物含有組成物、特に好ましくはポリグリセリン脂肪酸 エステルの構成脂肪酸が不飽和脂肪酸であることを特徴とする上記記載のゥコン抽 出物含有組成物、極めて好ましくは親油性乳化剤がジグリセリンモノォレイン酸エス テルであることを特徴とする上記記載のゥコン抽出物含有組成物、最も好ましくはマ ルチプル 'リスク'ファクター症候群を予防又は改善する効果を有することを特徴とす る上記記載のゥコン抽出物含有組成物、に関する。  [0008] That is, a first aspect of the present invention is that a lipophilic emulsifier containing a corn extract in an amount of more than 40% by weight, and having a medium chain fatty acid triglyceride and Z or fat and / or HLB value of 8.5 or less. The present invention relates to a composition comprising a grape extract. A preferred embodiment relates to the composition described above, characterized by comprising a medium-chain fatty acid triglyceride and a lipophilic emulsifier having a Z or HLB value of 8.5 or less. More preferably, the lipophilic emulsifier is a glycerin fatty acid ester, the composition containing a coconut extract described above, and further preferably, the lipophilic emulsifier is a polyglycerin fatty acid ester. The corn extract extract-containing composition, particularly preferably the corn extract extract-containing composition described above, wherein the constituent fatty acids of the polyglycerin fatty acid ester are unsaturated fatty acids, and very preferably the lipophilic emulsifier is diglycerin monoester. The above-mentioned composition comprising a cocoon extract, which is an ester of oleic acid, and most preferably the effect of preventing or ameliorating multiple 'risk' factor syndrome. Extract-containing composition.
[0009] 本発明の第 2は、上記記載の組成物を封入してなるカプセルに関する。 [0009] A second aspect of the present invention relates to a capsule enclosing the above-described composition.
[0010] ゥコン抽出物を高濃度に含有するにもかかわらず、粘度が高くなぐ且つ容器など への付着性が低い組成物を提供できる。従って、例えばゥコンの有用成分を高濃度 でソフトカプセル等へ封入することも容易になる。 [0010] A composition having a high viscosity and a low adherence to a container or the like can be provided despite containing a high concentration of a corn extract. Therefore, for example, it becomes easy to encapsulate the useful component of the cocoon in a soft capsule or the like at a high concentration.
発明の効果  The invention's effect
[0011] 本発明のゥコン抽出物含有組成物は、極めて有用な生理活性を有するものの、高粘 度で粘結性を有し流動性が悪く容器への付着が多レ、とレ、う問題を有する高濃度のゥ コン抽出物に、中鎖脂肪酸トリグリセリド及び/又は油脂及び Z又は HLB値が 8. 5 以下の親油性乳化剤を混合することにより、流動性、付着性および均一性に優れる という利点を有する。また本発明のゥコン抽出物含有組成物は高濃度のゥコン抽出 物を含有するのでマルチプル'リスク'ファクター症候群の予防又は改善する効果を 有するという利点を有する。更に本発明のゥコン抽出物含有組成物は流動性、付着 性および均一性に優れるので、高濃度のゥコン抽出物を封入したソフトカプセルを容 易に製造できるという利点を有する。 [0011] Although the composition of the present invention has a very useful physiological activity, it has a high viscosity, a caking property, a poor fluidity and often adheres to a container. By mixing a medium-concentrated triglyceride and / or fat and oil and a lipophilic emulsifier having a Z or HLB value of 8.5 or less with a high-concentration corn extract having a high concentration, the fluidity, adhesion and uniformity are excellent. Has advantages. In addition, the composition containing the cocoon extract of the present invention has an advantage that it has an effect of preventing or ameliorating multiple 'risk' factor syndromes because it contains a high concentration of the cocoon extract. Furthermore, since the composition containing a cocoon extract of the present invention is excellent in fluidity, adhesion and uniformity, a soft capsule containing a high-concentration cocoon extract can be used. It has the advantage that it can be easily manufactured.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0012] 以下に、本発明を詳しく説明する。本発明のゥコン抽出物含有組成物は、ゥコン抽 出物に対し、流動性を改善する油脂成分、及び/又は、粘結牲を改善する親油性 乳化剤を配合してなるものである。 Hereinafter, the present invention will be described in detail. The cocoon extract-containing composition of the present invention is obtained by mixing a cocoon extract with an oil component, which improves fluidity, and / or a lipophilic emulsifier, which improves cohesion.
[0013] 本発明のゥコン抽出物の製法は特に限定されず、従来からの公知の方法、例えば ゥコンの根茎部を温エタノールで抽出する方法により得ることが可能である。また、巿 販のゥコンォレオレジンをそのまま用いることも可能である。 [0013] The method for producing the icon extract of the present invention is not particularly limited, and it can be obtained by a conventionally known method, for example, a method of extracting the rhizome of the icon with warm ethanol. It is also possible to use commercially available Coneole Resin as it is.
[0014] 更に、本発明に用いるゥコン抽出物は、クルクミン、クルクミン誘導体 (例えば、デメト キシクルクミン、ビスデメトキシクルクミン、ジヒドロクルクミン、テトラヒドロクルクミン、へ キサヒドロクルクミン、ジヒドロキシテトラクルクミン等)及び、ピサボラン型セスキテルべ ンとして、例えば、 一ビサボレン、 α—クルクメン、ジンギベレン、 一セスキフエランド レン、 ar—ターメロン、 α—ターメロン、 ;3—ターメロン等を含有する。  [0014] Further, the iconic extract used in the present invention includes curcumin, curcumin derivatives (eg, demethoxycurcumin, bisdemethoxycurcumin, dihydrocurcumin, tetrahydrocurcumin, hexahydrocurcumin, dihydroxytetracurcumin, etc.) and pisaborane-type The sesquiterbene includes, for example, 1-bisabolene, α-curcumene, gingiberene, 1-sesquiferandrene, ar-turmerone, α-turmerone, and 3-turmerone.
[0015] 本発明に用いられる中鎖脂肪酸トリグリセリド (以下 MCTとも記載する)は、構成脂 肪酸残基として炭素数 6— 10の脂肪酸残基を有するトリグリセリドである。  [0015] The medium-chain fatty acid triglyceride (hereinafter also referred to as MCT) used in the present invention is a triglyceride having a fatty acid residue having 6 to 10 carbon atoms as a constituent fatty acid residue.
[0016] 本発明に用いられる油脂は、中鎖脂肪酸トリグリセリド以外の食用油脂のことであり 、それ以外に特に限定は無レ、。例えば、コーン油、ナタネ油、ハイエルシンナタネ油 、大豆油、ォリーブ油、紅花油、綿実油、ヒマヮリ油、米糠油、パーム油、パーム核油 等の植物油、魚油、牛脂、豚脂、乳脂、卵黄油等の動物油、又はこれらを原料として 分別、水添、エステル交換等を行った油脂、或いはこれらの混合油が使用できる。ま た、食品以外の用途であれば上記動植物油脂以外の油脂を選択することも可能であ る。  [0016] The fats and oils used in the present invention are edible fats and oils other than medium-chain fatty acid triglycerides, and are not particularly limited. For example, vegetable oils such as corn oil, rapeseed oil, high cinnamon rape oil, soybean oil, olive oil, safflower oil, cottonseed oil, castor oil, rice bran oil, palm oil, palm kernel oil, etc., fish oil, beef tallow, lard, milk fat, egg yolk Animal oils such as oils, oils and fats which have been subjected to separation, hydrogenation, transesterification and the like using these as raw materials, or mixed oils thereof can be used. For applications other than foods, it is also possible to select fats and oils other than the above animal and vegetable fats and oils.
[0017] 本発明に用いられる親油性乳化剤としてはゥコン抽出物又はゥコン抽出物及び油 脂と均一に混合できれば特に限定されないが、 HLB値は 8. 5以下が好ましぐより好 ましくは 3— 8. 5、更に好ましくは 5— 8. 5である。これは、ゥコンの抽出を行う際に使 用する溶剤の親油性に近い方が好ましいためである。但し、ここで言う親油性とは油 脂に溶解可能と言うことであり、 MCTや一般の食用油脂に溶解可能なものを親油性 乳化剤とする。 HLB値が 8. 5を超えると、ゥコン抽出物及び油脂と乳化剤とが分離 する場合がある。 [0017] The lipophilic emulsifier used in the present invention is not particularly limited as long as it can be uniformly mixed with the cocoon extract or the cocoon extract and fats and oils, but the HLB value is preferably 8.5 or less, more preferably 3 or less. —8.5, more preferably 5-8.5. This is because it is preferable that the solvent used for extracting the cocoon be closer to the lipophilicity. However, the lipophilicity mentioned here means that it can be dissolved in fats and oils, and those that can be dissolved in MCT or general edible fats and oils are defined as lipophilic emulsifiers. When the HLB value exceeds 8.5, emulsifiers are separated from cocoon extract and oils and fats May be.
[0018] 尚、 HLB値とは、一般に乳化剤の親水性と親油性の程度を表す尺度であり、その 値が小さいほど親油性が強い。 HLB値の求め方は特に限定するものではなレ、が、例 えば、下式により求めることができる(ィ匕学辞典、東京化学同人、第 1版、 1994年 10 月 1日発行参照)。  [0018] The HLB value is generally a measure of the degree of hydrophilicity and lipophilicity of an emulsifier, and the smaller the value, the stronger the lipophilicity. The method for determining the HLB value is not particularly limited, but can be determined, for example, by the following formula (see Dani Gakushi Dictionary, Tokyo Kagaku Dojin, 1st edition, published on October 1, 1994).
[0019] HLB = 20 X (l-S/A)  [0019] HLB = 20 X (l-S / A)
S:エステルのケンィヒ価、 A:脂肪酸の酸価  S: Känig value of ester, A: Acid value of fatty acid
この様な乳化剤としては、例えばモノグリセリン脂肪酸エステル、モノグリセリン脂肪 酸有機酸エステル、ポリグリセリン脂肪酸エステル、ポリグリセリン縮合リシノール酸ェ ステル等のグリセリン脂肪酸エステル類、ソルビタン脂肪酸エステル類、ポリソルベー ト類、ショ糖脂肪酸エステル類、プロピレングリコール脂肪酸エステル類、レシチン類 等が挙げられ、それぞれ少なくとも 1種を混合して使用することができる。中でも、効 果的に粘結性を改善できることからグリセリン脂肪酸エステル類が好ましぐポリグリセ リン脂肪酸エステル、ポリグリセリン縮合リシノール酸エステルがより好ましい。本発明 で言う粘結性とは、流動性、容器への付着性、ゥコン抽出物含有組成物各成分の均 一性のバランスを意味し、前記 3種の性質が良好な程、粘結性も良いことを意味する  Examples of such emulsifiers include glycerin fatty acid esters such as monoglycerin fatty acid ester, monoglycerin fatty acid organic acid ester, polyglycerin fatty acid ester, polyglycerin condensed ricinoleate ester, sorbitan fatty acid esters, polysorbates, Sugar fatty acid esters, propylene glycol fatty acid esters, lecithin and the like can be mentioned, and at least one of them can be used in combination. Among them, polyglycerin fatty acid esters and polyglycerin condensed ricinoleate are more preferable, since glycerin fatty acid esters are preferred because they can effectively improve the caking property. The caking property as referred to in the present invention means a balance between fluidity, adhesion to a container, and uniformity of each component of a composition containing a cocoon extract. The better the above three properties, the better the caking property. Also means good
[0020] 前記ポリグリセリン脂肪酸エステル及びポリグリセリン縮合リシノール酸エステルとし ては、ポリグリセリンの平均重合度が 2— 10が例示される。更に、ポリグリセリン脂肪酸 エステルは構成脂肪酸の炭素数が 6— 22の脂肪酸であるものが例示され、中でも構 成脂肪酸が不飽和脂肪酸であることが好ましぐ例えば、ジグリセリンモノォレイン酸 エステル、テトラグリセリンペンタォレイン酸エステル、へキサグリセリンペンタォレイン 酸エステル、ペンタグリセリントリオレイン酸エステル、デカグリセリンペンタォレイン酸 エステル、デカグリセリンデカオレイン酸エステル、デカグリセリンデ力エル力酸エステ ル等が好適であり、より好ましくは、ジグリセリンモノォレイン酸エステルである。 [0020] Examples of the polyglycerin fatty acid ester and the polyglycerin condensed ricinoleate include an average degree of polymerization of polyglycerin of 2 to 10. Further, examples of the polyglycerin fatty acid ester include those in which the constituent fatty acid is a fatty acid having 6 to 22 carbon atoms. Among them, the constituent fatty acid is preferably an unsaturated fatty acid. For example, diglycerin monooleate, Tetraglycerin pentaoleate, hexaglycerin pentaoleate, pentaglycerin trioleate, decaglycerin pentaoleate, decaglycerin decaoleate, decaglycerin depot oleate, etc. Preferred and more preferred are diglycerin monooleates.
[0021] 前記 MCT、油脂、 HLB値力 S8. 5以下の親油性乳化剤は、ゥコン抽出物と均一に 混合できるのであれば、それらの内少なくとも 1種を用いることができる。ゥコン抽出物 の含有量が増える程、 MCT及び Z又は HLB値が 8. 5以下の親油性乳化剤が好ま しぐ MCT及び HLB値が 8. 5以下の親油性乳化剤の混合物がより好ましい。 MCT は、一般の油脂に比べて粘度が低ぐ且つ体脂肪抑制効果が知られており、一般の 油脂と比べて均一且つ微細なスラリーとなるために流動性及び均一性の改善効果が 大きぐ HLB値が 8. 5以下の親油性乳化剤は、付着性の改善効果が大きい。 [0021] As the lipophilic emulsifier having an MCT, fat or HLB value of S8.5 or less, at least one of them can be used as long as it can be uniformly mixed with a cocoon extract.程 As the content of corn extract increases, lipophilic emulsifiers with MCT and Z or HLB values of 8.5 or less are preferred. A mixture of lipophilic emulsifiers having an MCT and HLB value of 8.5 or less is more preferred. MCT is known to have a lower viscosity than general fats and oils and an effect of suppressing body fat.It is a uniform and fine slurry compared to general fats and oils, and has a large effect of improving fluidity and uniformity. A lipophilic emulsifier having an HLB value of 8.5 or less has a large effect of improving adhesion.
[0022] ここでゥコン抽出物含有組成物中のゥコン抽出物と中鎖脂肪酸トリグリセリド及び/ 又は油脂及び Z又は HLB値が 8. 5以下の親油性乳化剤の含有量について詳述す る。本発明の中鎖脂肪酸トリグリセリド及び/又は油脂及び/又は及び Z又は HLB 値が 8. 5以下の親油性乳化剤とは、 MCT単独、油脂単独、 HLB値力 5以下の 親油性乳化剤単独、 MCTと油脂の併用、 MCTと HLB値力 5以下の親油性乳化 剤との併用、油脂と HLB値が 8. 5以下の親油性乳化剤との併用、 MCTと油脂と HL B値が 8. 5以下の親油性乳化剤との併用、である。これらの組み合わせは、ゥコン抽 出物の含有量によって適宜選択することができる。 Here, the contents of the cocoon extract, the medium-chain fatty acid triglyceride and / or the fat and oil, and the lipophilic emulsifier having a Z or HLB value of 8.5 or less in the cocoon extract-containing composition will be described in detail. The lipophilic emulsifier having a medium chain fatty acid triglyceride and / or fat and / or Z or HLB value of 8.5 or less according to the present invention includes MCT alone, fat and oil alone, lipophilic emulsifier alone having an HLB value of 5 or less, MCT and Combination of fats and oils, Combination of MCT and lipophilic emulsifier with HLB value of 5 or less, Combination of fats and oils with lipophilic emulsifier with HLB value of 8.5 or less, MCT and fat with HLB value of 8.5 or less Combined with a lipophilic emulsifier. These combinations can be appropriately selected depending on the content of the Japanese extract.
[0023] 即ち、ゥコン抽出物含有組成物中のゥコン抽出物含有量が 40重量%以下の場合、 MCT及び/又は油脂及び/又は HLB値が 8. 5以下の親油性乳化剤は 60重量% 以上である。この場合、 MCT単独、油脂単独、親油性乳化剤単独、 MCTと油脂の 併用、 MCTと親油性乳化剤との併用、油脂と親油性乳化剤との併用、 MCTと油脂 と親油性乳化剤との併用、何れの組み合わせでも良レ、。  [0023] That is, when the content of the coconut extract in the composition containing the coconut extract is 40% by weight or less, the lipophilic emulsifier having an MCT and / or fat and / or HLB value of 8.5 or less is 60% by weight or more. It is. In this case, MCT alone, fat alone, lipophilic emulsifier alone, combined use of MCT and fat, combined use of MCT and lipophilic emulsifier, combined use of fat and oil with lipophilic emulsifier, combined use of MCT with fat and oil and lipophilic emulsifier Good combination of,
[0024] 同様に、ゥコン抽出物含有量力 0重量%を超えて 50重量%未満の場合は、 MCT 単独、親油性乳化剤単独、 MCTと油脂の併用、 MCTと親油性乳化剤との併用、油 脂と親油性乳化剤との併用、 MCTと油脂と親油性乳化剤との併用、何れの組み合 わせでも良ぐその総量は 50重量%を超えて、且つ 60重量%未満の範囲である。油 脂単独では粘結性の改善効果が実用的でない場合があるため、 MCTとの併用もし くは、親油性乳化剤との併用が好ましぐ油脂と親油性乳化剤の重量比率は 99. 9/ 0. 1—0. 1/99. 9カ好ましく、より好ましく fま 90/10— 0. 1/99. 9である。流動 性を優先する場合は油脂の比率を高ぐ付着性の改善を優先する場合は親油性乳 化剤の重量比率をそれぞれ高く設定することが好ましい。  [0024] Similarly, when the content of the iconic extract is more than 0% by weight and less than 50% by weight, MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat or oil, a combination of MCT and a lipophilic emulsifier, a fat or oil, The combined amount of MCT, lipophilic emulsifier, and MCT, fat and oil, and lipophilic emulsifier in any combination is more than 50% by weight and less than 60% by weight. Since the effect of improving caking properties may not be practical with fats and oils alone, the weight ratio of fats and fats to lipophilic emulsifiers, which is preferably used in combination with MCT or with lipophilic emulsifiers, is 99.9 / 0.1-0.1 / 99.9 is preferred, and more preferably 90/10-0.1 / 99.9. It is preferable to set the weight ratio of the lipophilic emulsifier to be high in order to increase the ratio of fats and oils when the priority is placed on the fluidity and to improve the adhesion.
[0025] また、ゥコン抽出物含有量が 50重量%以上、且つ 60重量%未満の場合は、 MCT 単独、親油性乳化剤単独、 MCTと油脂の併用、 MCTと親油性乳化剤との併用、油 脂と親油性乳化剤との併用、 MCTと油脂と親油性乳化剤との併用、何れの組み合 わせでも良ぐその総量は 40重量%を超えて、且つ 50重量%以下の範囲である。油 脂単独では粘結性の改善効果が十分でなレ、場合があるため、油脂と MCTとの併用 もしくは、油脂と親油性乳化剤との併用が好ましぐ流動性と付着性両方の大きな改 善を達成しょうとすると、 MCTと親油性乳化剤との併用がより好ましい。油脂と親油 性乳化剤との併用の場合の油脂と親油性乳化剤の重量比率は 90Z10 0. 1/99 . 9力 S好ましく、より好ましく fま 75/25—0. 1/99. 9であり、ゥコン由出物含有量力 4 0重量%を超えて 50重量%未満の場合に比べて乳化剤比率が高い範囲設定となる 。油脂と MCTとの併用の場合の油脂と MCTの重量比率は、 90/10—0. 1/99. 9カ好ましく、より好ましく fま 70/30— 0. 1/99. 9、更に好ましく fま 50/50— 0. 1 /99. 9であり、ゥコン抽出物含有量力 ¾0重量%を超えて 50重量%未満の場合に 比べて MCT比率が高レ、範囲設定となる。流動性を優先する場合は油脂の比率を高 ぐ付着性の改善を優先する場合は親油性乳化剤の重量比率をそれぞれ高く設定 することが好ましい。また、 MCTと親油性乳化剤との併用の場合の MCTと親油性乳 化剤の重量比率は 90/10— 10/90が好ましい。この範囲であれば、流動性と付着 性が共に大きく改善される。 [0025] When the content of the cocoon extract is 50% by weight or more and less than 60% by weight, MCT alone, a lipophilic emulsifier alone, a combination of MCT and a fat, a combination of MCT and a lipophilic emulsifier, Combinations of fats and lipophilic emulsifiers, combined use of MCTs and fats and lipophilic emulsifiers, in any combination, the total amount is more than 40% by weight and not more than 50% by weight. Since fats and oils alone may not sufficiently improve the caking properties, the combination of fats and oils with MCTs or the combination of fats and oils with a lipophilic emulsifier is preferred, and both fluidity and adhesion are greatly improved. To achieve good, a combination of MCT and lipophilic emulsifier is more preferable. When the fat and oil and the lipophilic emulsifier are used in combination, the weight ratio of the fat and oil to the lipophilic emulsifier is preferably 90Z10 0.1 / 99.9 force S, more preferably 75 / 25-0.1 / 99.9. The emulsifier ratio is set in a range higher than the case where the content of the product derived from corn is more than 40 wt% and less than 50 wt%. The weight ratio of oil and fat to MCT when using oil and fat together with MCT is preferably 90 / 10-0.1 / 99.9, more preferably 70 / 30-0.1 / 99.9, and even more preferably f. In addition, the ratio is 50 / 50-0.1 / 99.9, and the MCT ratio is higher and the range is set as compared with the case where the content of konkon extract is more than 0% and less than 50% by weight. It is preferable to set the weight ratio of the lipophilic emulsifier to be higher in order to increase the ratio of fats and oils when the priority is given to the fluidity and to prioritize the improvement in adhesion. When MCT is used in combination with a lipophilic emulsifier, the weight ratio of MCT to the lipophilic emulsifier is preferably 90/10 to 10/90. Within this range, both fluidity and adhesion are significantly improved.
[0026] 更には、ゥコン抽出物含有量が 60重量%以上の場合は、 MCTと親油性乳化剤と の併用、油脂と親油性乳化剤との併用、 MCTと油脂と親油性乳化剤との併用が好ま しぐ中でも MCTと親油性乳化剤の併用がより好ましぐその総量は 40重量%以下 である。 MCTと親油性乳化剤を併用する場合、 MCTと親油性乳化剤の重量比率は 特に限定されないが、好ましくは 0. 1/99. 9一 99. 9/0. 1、より好ましくは 10/9 0—90/10、更に好ましくは、 25/75—75/25,最も好ましくは 40/60— 60/4 0の範囲であり、流動性を優先する場合は油脂の比率を高ぐ付着牲の改善を優先 する場合は親油性乳化剤の重量比率をそれぞれ高く設定することが好ましい。  [0026] Further, when the content of the cocoon extract is 60% by weight or more, the combination use of MCT and a lipophilic emulsifier, the combination use of a fat and oil with a lipophilic emulsifier, and the combination use of MCT with a fat and oil and a lipophilic emulsifier are preferred. Amongst the combinations, the combined amount of MCT and lipophilic emulsifier is more preferable, and the total amount is less than 40% by weight. When MCT and a lipophilic emulsifier are used in combination, the weight ratio of the MCT to the lipophilic emulsifier is not particularly limited, but is preferably 0.1 / 99.9 to 99.9 / 0.1, more preferably 10/90. 90/10, more preferably 25 / 75-75 / 25, and most preferably 40 / 60-60 / 40. When fluidity is prioritized, the ratio of fats and oils is increased to improve adhesion. If priority is given, it is preferable to set the weight ratio of the lipophilic emulsifier to be high.
[0027] ゥコン抽出物含有組成物の調整は、必要に応じて加温条件下で行うことが好ましく 、 20— 60°C程度で調整することがより好ましい。具体的には、調整に際しては、所定 量のゥコン抽出物と所定量の油脂及び Z又は親油性乳化剤を、所定の温度での加 温条件下で撹拌により均一に混合すればよぐ例えばパドルミキサー、ホモミキサー、 ホモジナイザー、高圧ホモジナイザー、コロイドミノレ、ビーズミル等を用いることができ る。 [0027] The composition of the icon extract is preferably adjusted under heating conditions as needed, and more preferably at about 20-60 ° C. Specifically, for adjustment, a predetermined amount of a cocoon extract and a predetermined amount of fats and oils or Z or a lipophilic emulsifier may be uniformly mixed by stirring under a predetermined temperature heating condition, for example, a paddle mixer. , Homomixer, A homogenizer, a high-pressure homogenizer, a colloid minole, a bead mill, or the like can be used.
[0028] 上述の方法により調整されたゥコン抽出物含有組成物は、そのまま食品へ添加す ることも可能である力 より効果的に摂取するためにはカプセル形態とするのが好まし く、例えば、ソフトカプセル、ハードカプセル、シームレスカプセル等を用いることがで きる。更にゥコン抽出物組成物に対して、 目的に応じて、ビタミン A, C, D, E等の各 種ビタミン類、ミツロウ等の製剤用基剤等を更に添加してもよい。また、マルチプル'リ スク 'ファクター症候群を予防又は改善する効果を有する甘草疎水性抽出物、クロー ブ抽出物、シナモン抽出物等、あるいは一般に食品として用いられる素材、及び抗 酸化剤等の食品添加物を添加してもよい。  [0028] The composition containing the radish extract prepared by the above-described method is preferably in the form of a capsule for more effective ingestion than the power that can be added to food as it is. , Soft capsules, hard capsules, seamless capsules and the like can be used. Furthermore, various vitamins such as vitamins A, C, D, and E, and a formulation base such as beeswax and the like may be further added to the icon extract composition according to the purpose. In addition, licorice hydrophobic extract, clove extract, cinnamon extract, etc., which has the effect of preventing or ameliorating multiple 'risk' factor syndrome, or materials commonly used as foods, and food additives such as antioxidants May be added.
実施例  Example
[0029] 以下、実施例を挙げて本発明を更に具体的に説明するが、本発明はこれらの実施 例に限定されるものではない。  Hereinafter, the present invention will be described more specifically with reference to Examples, but the present invention is not limited to these Examples.
[0030] <流動性評価法 > <Flowability evaluation method>
50ccガラスビーカーにゥコン抽出物含有組成物を 20g入れ、 25°Cにおいてビーカ 一を下方 45度に傾けた時の状態を観察した。その評価基準については以下の通り である。  20 g of the icon extract-containing composition was placed in a 50 cc glass beaker, and the state when the beaker was tilted at 45 ° downward at 25 ° C. was observed. The evaluation criteria are as follows.
◎:速やかに流れ出る、〇:ゆっくりと流れ出る、 A : 40°Cに加温するとゆっくりと流れ 出る、 X : 40°Cに加温してもほとんど流れ出なレ、、※:撹拌しても乳化剤が均一にな らず、分離した状態で評価できない。  ◎: Flows out quickly, △: Flows out slowly, A: Flows out slowly when heated to 40 ° C, X: Almost flows out even when heated to 40 ° C, *: Emulsifier even when stirred Is not uniform and cannot be evaluated in a separated state.
[0031] ぐ付着性評価法 >  [0031] Gug adhesion evaluation method>
50ccガラスビーカーにゥコン抽出物含有組成物を 20g入れ、 25°Cにおいてビーカ 一を下方 45度に傾けた後、ビーカーを元に戻して 30分静置後のビーカー内壁の状 態を観察した。その評価基準については以下の通りである。◎:内壁への付着無し、 〇:僅かに内壁への付着有り、△:内壁へ粒状の付着有り、 X:べっとりと内壁へ付着 、※:撹拌しても乳化剤が均一にならず、分離した状態で評価できない。  20 g of the icon extract-containing composition was placed in a 50 cc glass beaker, the beaker was tilted downward at 45 ° C. at 25 ° C., the beaker was returned to its original position, and the state of the inner wall of the beaker after standing for 30 minutes was observed. The evaluation criteria are as follows. ◎: No adhesion to inner wall, 〇: Slight adhesion to inner wall, △: Granular adhesion to inner wall, X: Adhesive and stick to inner wall, *: Emulsifier was not uniform even after stirring and separated Can not be evaluated in the state
[0032] <均一性評価法 >  [0032] <Uniformity evaluation method>
ゥコン抽出物含有組成物の外観及び、内相を観察した。その評価基準については 以下の通りである。◎:均一で微細なスラリー状態、〇:均一であるが、粒状感のある スラリー状態、△:撹拌すると均一になるが、静置すると短時間で固液分離した状態、ゥ The appearance and the internal phase of the composition containing the konkon extract were observed. About the evaluation criteria It is as follows. ◎: uniform and fine slurry state, 〇: uniform but granular slurry state, △: uniform when stirred, but solid-liquid separation in a short time when allowed to stand,
X:撹拌しても乳化剤が均一にならず、分離した状態。 X: The emulsifier was not uniform even after stirring, but separated.
[0033] (実施例 1)  (Example 1)
ゥコンォレオレジン(丸善製薬株式会社製:タルクミノイド 31%、テルペン類 39%含 有) 50重量%、 MCT (理研ビタミン株式会社製、商品名:アクター M2) 25重量%、 ジグリセリンモノォレイン酸エステル (理研ビタミン株式会社製、商品名:ポエム D〇_l 00V、 HLB値 = 8. 0) 25重量%を用レ、、 40°C加温条件下でパドルミキサーにより混 合した。得られたゥコン抽出物含有組成物は、流動性、付着性及び均一性が大きく 改善され、即ち粘結性が大きく改善された非常に良好な性状を示した (表 1)。  ゥ Conoleo resin (Maruzen Pharmaceutical Co., Ltd .: Talcminoid 31%, Terpenes 39%) 50% by weight, MCT (RIKEN Vitamin Co., Ltd., trade name: Actor M2) 25% by weight, Diglycerin monoolein An acid ester (manufactured by Riken Vitamin Co., Ltd., trade name: Poem D〇_100V, HLB value = 8.0) was used in an amount of 25% by weight, and mixed with a paddle mixer under heating conditions of 40 ° C. The composition containing the extracted radish extract showed significantly improved fluidity, adhesion and uniformity, that is, very good properties with greatly improved caking properties (Table 1).
[0034] (実施例 2)  (Example 2)
ゥコンォレオレジン(丸善製薬株式会社製) 50重量%、 MCT (理研ビタミン株式会 社製、商品名:アクター M2) 37· 5重量0 /0、ジグリセリンモノォレイン酸エステル (理研 ビタミン株式会社製、商品名:ポエム DO—100V, HLB値 =8. 0) 12. 5重量%を用 レ、、 40°C加温条件下でパドルミキサーにより混合した。得られたゥコン抽出物含有組 成物は、流動性、付着性及び均一性が大きく改善され、即ち粘結性が大きく改善さ れた非常に良好な性状を示した (表 1)。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 50 wt%, MCT (Riken Vitamin Stock Company, Ltd., trade name: actor M2) 37 · 5 weight 0/0, diglycerol mono O rain acid ester (Riken Vitamin stock Made by the company, trade name: Poem DO-100V, HLB value = 8.0) 12.5% by weight was mixed with a paddle mixer under heating conditions of 40 ° C. The obtained composition containing the icon extract had significantly improved fluidity, adhesion and uniformity, that is, exhibited very good properties with greatly improved caking properties (Table 1).
[0035] (実施例 3)  (Example 3)
ゥコンォレオレジン(丸善製薬株式会社製) 50重量0 /0、 MCT (理研ビタミン株式会 社製、商品名:アクター M2) 12· 5重量0 /0、ジグリセリンモノォレイン酸エステル (理研 ビタミン株式会社製、商品名:ポエム DO—100V, HLB値 =8. 0) 37. 5重量%を用 レ、、 40°C加温条件下でパドルミキサーにより混合した。得られたゥコン抽出物含有組 成物は、流動性、付着性及び均一性が大きく改善され、即ち粘結性が大きく改善さ れた非常に良好な性状を示した (表 1)。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 50 weight 0/0, MCT (Riken Vitamin Stock Company, Ltd., trade name: actor M2) 12 · 5 weight 0/0, diglycerol mono O rain acid ester (RIKEN Vitamin Co., Ltd., trade name: Poem DO-100V, HLB value = 8.0) 37.5% by weight was mixed with a paddle mixer under heating conditions of 40 ° C. The obtained composition containing the icon extract had significantly improved fluidity, adhesion and uniformity, that is, exhibited very good properties with greatly improved caking properties (Table 1).
[0036] (実施例 4)  (Example 4)
ゥコンォレオレジン(丸善製薬株式会社製) 80重量%、 MCT (理研ビタミン株式会 社製、商品名:アクター M2) 10重量0 /0、ジグリセリンモノォレイン酸エステル (理研ビ タミン株式会社製、商品名:ポエム DO— 100V, HLB値 = 8. 0) 10重量%を用い、 4 o°c加温条件下でパドルミキサーにより混合した。得られたゥコン抽出物含有組成物 は、流動性及び付着性が改善され、且つ均一性が大きく改善され、即ち粘結性が改 善された良好な性状を示した (表 1)。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 80 wt%, MCT (Riken Vitamin Stock Company, Ltd., trade name: actor M2) 10 weight 0/0, diglycerol mono O rain acid ester (Riken vitamin Co., Ltd. Product name: Poem DO—100V, HLB value = 8.0) 10% by weight The mixture was mixed with a paddle mixer under o ° c heating conditions. The obtained composition containing the radish extract had good properties with improved fluidity and adhesion, and greatly improved uniformity, that is, improved caking properties (Table 1).
[0037] (実施例 5)  (Example 5)
ゥコンォレオレジン(丸善製薬株式会社製) 50重量%、 MCT (理研ビタミン株式会 社製、商品名:アクター M2) 5重量0 /0、ペンタグリセリントリオレイン酸エステル (太陽 化学株式会社製、商品名:サンフアット A— 173E, HLB値 = 7. 0) 45重量%を用い 、 40°C加温条件下でパドルミキサーにより混合した。得られたゥコン抽出物含有組成 物は、流動性が改善され、且つ付着性及び均一性が大きく改善され、粘結性が改善 された良好な性状を示した (表 1)。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 50 wt%, MCT (Riken Vitamin Stock Company, Ltd., trade name: actor M2) 5 weight 0/0, penta-glycerol trioleate (Taiyo Chemical Co., Ltd., Trade name: Sun Fat A-173E, HLB value = 7.0) 45% by weight was mixed with a paddle mixer under heating conditions of 40 ° C. The obtained composition containing the icon extract had good properties in which the fluidity was improved, the adhesion and the uniformity were greatly improved, and the caking property was improved (Table 1).
[0038] (実施例 6)  (Example 6)
ゥコンォレオレジン(丸善製薬株式会社製) 50重量%、 MCT (理研ビタミン株式会 社製、商品名:アクター M2) 45重量0 /0、へキサグリセリンペンタォレイン酸エステル( 阪本薬品工業株式会社製、商品名: SYグリスター PO— 5S, HLB値 =4. 9) 5重量 %を用い、 40°C加温条件下でパドルミキサーにより混合した。得られたゥコン抽出物 含有組成物は、流動性及び均一性が大きく改善され、且つ付着性が改善され、粘結 性が改善された良好な性状を示した (表 1)。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 50 wt%, MCT (Riken Vitamin Stock Company, Ltd., trade name: actor M2) 45 weight 0/0, to Kisa glycerin penta-O rain acid esters (Sakamoto Yakuhin Kogyo stock Company name, trade name: SY Glister PO-5S, HLB value = 4.9) 5% by weight was mixed with a paddle mixer under heating conditions of 40 ° C. The obtained composition containing the radish extract showed excellent properties in which fluidity and uniformity were greatly improved, adhesion was improved, and caking property was improved (Table 1).
[0039] (実施例 7)  (Example 7)
ゥコンォレオレジン(丸善製薬株式会社製) 45重量%、 MCT (理研ビタミン株式会 社製、商品名:アクター M2) 55重量%を用い、 40°C加温条件下でパドルミキサーに より混合した。得られたゥコン抽出物含有組成物は、流動性が大きく改善され、且つ 付着性及び均一性が改善され、粘結性が改善された良好な性状を示した (表 1)。  ゥ Using 45% by weight of Conoleoresin (manufactured by Maruzen Pharmaceutical Co., Ltd.) and 55% by weight of MCT (manufactured by Riken Vitamin Co., Ltd., trade name: Actor M2), mixed with a paddle mixer under heating conditions of 40 ° C. did. The obtained composition containing the radish extract showed excellent properties in which flowability was greatly improved, adhesion and uniformity were improved, and caking property was improved (Table 1).
[0040] (実施例 8)  (Example 8)
ゥコンォレオレジン(丸善製薬株式会社製) 45重量0 /0、ジグリセリンモノォレイン酸 エステル(理研ビタミン株式会社製、商品名:ポエム D〇— 100V, HLB値 =8. 0) 55 重量%を用い、 40°C加温条件下でパドルミキサーにより混合した。得られたゥコン抽 出物含有組成物は、流動性及び均一性が改善され、且つ付着性が大きく改善され、 粘結性が改善された良好な性状を示した (表 1)。 [0041] (実施例 9) © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 45 weight 0/0, diglycerol mono O rain acid ester (manufactured by Riken Vitamin Co., Ltd., trade name:. Poem D_〇- 100V, HLB value = 8 0) 55 wt. % And mixed with a paddle mixer under heating conditions of 40 ° C. The obtained composition containing extract of starch extract showed good properties in which fluidity and uniformity were improved, adhesion was greatly improved, and caking property was improved (Table 1). (Example 9)
実施例 1のゥコン抽出物含有組成物 300mg、ミツロウ 30mgを均一に混合した後、 ロータリー式ソフトカプセル製造装置を用いてゼラチン皮膜に圧入し、内容量 330m gのソフトカプセル剤を得た。調合タンク内およびソフトカプセル製造装置内への付着 による内容物の残存量はごく僅かであり、工業的に何ら問題のないことが確認された  After uniformly mixing 300 mg of the icon extract-containing composition of Example 1 and 30 mg of beeswax, the mixture was pressed into a gelatin film using a rotary soft capsule manufacturing apparatus to obtain a soft capsule having a content of 330 mg. The remaining amount of the contents due to adhesion in the mixing tank and the soft capsule manufacturing equipment was very small, and it was confirmed that there was no industrial problem.
[0042] (比較例 1) (Comparative Example 1)
ゥコンォレオレジン(丸善製薬株式会社製) 50重量%、 MCT (理研ビタミン株式会 社製,商品名:アクター M2) 25重量0 /0、テトラグリセリンモノォレイン酸エステル(阪本 薬品工業株式会社製,商品名: SYグリスター MO_3S, HLB値 = 8. 8) 25重量%を 用レ、、 40°C°C加温条件下でパドルミキサーにより混合した。得られたゥコン抽出物含 有組成物は乳化剤が分離し不均一な状態であり、流動性や付着性は評価できなか つた (表 1)。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 50 wt%, MCT (Riken Vitamin Stock Company, Ltd., trade name: actor M2) 25 weight 0/0, tetra glycerin mono O rain acid esters (Sakamoto Yakuhin Kogyo Co., Ltd. Product name: SY Glister MO_3S, HLB value = 8.8) 25% by weight was mixed with a paddle mixer under heating conditions of 40 ° C and ° C. The emulsifier was separated and the heterogeneous state was obtained in the obtained composition containing the icon extract, and its fluidity and adhesion could not be evaluated (Table 1).
[0043] (比較例 2)  (Comparative Example 2)
ゥコンォレオレジン (丸善製薬株式会社製) 40重量%、ゴマ油 (力ドャ製油株式会 社製) 55重量0 /0、モノグリセリンモノステアリン酸エステル (理研ビタミン株式会社製, 商品名:エマルジー MS, HLB値 =4. 3) 5重量%を用ぃ、40で加温条件下でパド ノレミキサーにより混合した。得られたゥコン抽出物含有組成物は、流動性は改善され ていたが付着性や均一性はあまり改善されておらず、粘結性の改善は必ずしも十分 とは言い難いものであった (表 1)。また、実施例 9と同様方法でソフトカプセルを作成 したところ、調合タンク内およびソフトカプセル製造装置内へ相当量の付着が確認さ れ、工業的には問題のあることが確認された。 © Con O Leo resin (Maruzen Pharmaceuticals Co., Ltd.) 40% by weight, sesame oil (made by force de turbocharger oil stock company) 55 weight 0/0, mono glycerin monostearate ester (Riken Vitamin Co., Ltd., trade name: EMALGEE MS, HLB value = 4.3) 5% by weight was used and mixed with a paddle mixer at 40 under heating conditions. Although the flowability of the obtained composition containing the starch extract was improved, the adhesiveness and uniformity were not significantly improved, and the improvement of the caking property was not necessarily sufficient (see Table 1). 1). In addition, when soft capsules were prepared in the same manner as in Example 9, a considerable amount of adhesion was confirmed in the blending tank and the soft capsule manufacturing apparatus, and it was confirmed that there was a problem industrially.
[0044] (比較例 3)  (Comparative Example 3)
ゥコンォレオレジン (丸善製薬株式会社製) 45重量%、菜種油 (鐘淵化学工業株式 会社製) 55重量%を用い、 40°C加温条件下でパドルミキサーにより混合した。得ら れたゥコン抽出物含有組成物は、流動性、付着性、均一性何れもあまり改善されて おらず、粘結性の改善は必ずしも十分とは言い難レ、ものであった (表 1)。  Using 45% by weight of Konoleo Resin (manufactured by Maruzen Pharmaceutical Co., Ltd.) and 55% by weight of rapeseed oil (manufactured by Kaneka Chemical Industry Co., Ltd.), they were mixed with a paddle mixer under a heating condition of 40 ° C. In the obtained composition containing the radish extract, none of the fluidity, adhesion and uniformity were significantly improved, and the improvement of the caking property was not necessarily sufficient (Table 1). ).
[0045] (比較例 4) ゥコンォレオレジン(丸善製薬株式会社製) 100重量%、すなわち単独では流動性(Comparative Example 4) ゥ Coneole Resin (Maruzen Pharmaceutical Co., Ltd.) 100% by weight
、付着性共にかなり悪かった。 And the adhesion was very poor.
[表 1] 1  [Table 1] 1
Figure imgf000013_0001
産業上の利用可能性
Figure imgf000013_0001
Industrial applicability
ゥコン抽出物を高濃度に含有するにもかかわらず、粘度が高くなぐ且つ容器などへ の付着性が低い組成物を提供できる。従って、例えばゥコンの有用成分を高濃度で ソフトカプセル等へ封入することも容易になる。 Despite containing a high concentration of corn extract, it is possible to provide a composition having a high viscosity and low adhesion to containers and the like. Therefore, for example, it becomes easy to enclose useful components of the cocoon in a soft capsule or the like at a high concentration.

Claims

請求の範囲 The scope of the claims
[1] ゥコン抽出物を 40重量%を超えて含有し、且つ、中鎖脂肪酸トリグリセリド及び/又 は油脂及び Z又は HLB値が 8. 5以下の親油性乳化剤からなることを特徴とするゥコ ン抽出物含有組成物。  [1] A coconut extract containing more than 40% by weight of a corn extract and comprising a medium-chain fatty acid triglyceride and / or fat and oil and a lipophilic emulsifier having a Z or HLB value of 8.5 or less. Extract-containing composition.
[2] 中鎖脂肪酸トリグリセリド及び Z又は HLB値が 8. 5以下の親油性乳化剤からなること を特徴とする請求項 1記載のゥコン抽出物含有組成物。  [2] The composition of claim 1 comprising a medium-chain fatty acid triglyceride and a lipophilic emulsifier having a Z or HLB value of 8.5 or less.
[3] 親油性乳化剤がグリセリン脂肪酸エステルであることを特徴とする請求項 1又は 2に 記載のゥコン抽出物含有組成物。 [3] The composition of claim 1 or 2, wherein the lipophilic emulsifier is a glycerin fatty acid ester.
[4] 親油性乳化剤がポリグリセリン脂肪酸エステルであることを特徴とする請求項 1又は 2 に記載のゥコン抽出物含有組成物。 [4] The composition of claim 1 or 2, wherein the lipophilic emulsifier is a polyglycerin fatty acid ester.
[5] ポリグリセリン脂肪酸エステルの構成脂肪酸が不飽和であることを特徴とする請求項[5] The constituent fatty acid of the polyglycerin fatty acid ester is unsaturated.
4記載のゥコン抽出物含有組成物。 4. The composition according to item 4 containing a konkon extract.
[6] 親油性乳化剤がジグリセリンモノォレイン酸エステルであることを特徴とする請求項 1 又は 2に記載のゥコン抽出物含有組成物。 [6] The composition of claim 1 or 2, wherein the lipophilic emulsifier is diglycerin monooleate.
[7] マルチプル'リスク'ファクター症候群を予防又は改善する効果を有することを特徴と する請求項 1一 6の何れかに記載のゥコン抽出物含有組成物。 [7] The composition of claim 1, which has an effect of preventing or ameliorating multiple 'risk' factor syndromes.
[8] 請求項 1一 7の何れかに記載の組成物を封入してなるカプセル。 [8] A capsule in which the composition according to any one of claims 11 to 7 is encapsulated.
PCT/JP2005/005175 2004-03-31 2005-03-23 Turmeric extract-containing composition having improved caking capacity WO2005097152A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006511991A JPWO2005097152A1 (en) 2004-03-31 2005-03-23 Turmeric extract-containing composition with improved caking properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004107212 2004-03-31
JP2004-107212 2004-03-31

Publications (1)

Publication Number Publication Date
WO2005097152A1 true WO2005097152A1 (en) 2005-10-20

Family

ID=35124833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/005175 WO2005097152A1 (en) 2004-03-31 2005-03-23 Turmeric extract-containing composition having improved caking capacity

Country Status (2)

Country Link
JP (1) JPWO2005097152A1 (en)
WO (1) WO2005097152A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010043032A (en) * 2008-08-13 2010-02-25 Fuji Chem Ind Co Ltd High concentration astaxanthin extract
EP2410874A1 (en) * 2009-03-26 2012-02-01 Abbott Laboratories Nutritional composition comprising curcuminoids and methods of manufacture
JP2013202005A (en) * 2012-03-29 2013-10-07 National Agriculture & Food Research Organization Curcumin-containing oil and fat, and method for producing the same
JP2015527361A (en) * 2012-08-21 2015-09-17 カリフォルニア ノースステイト カレッジ オブ ファーマシー, エルエルシーCalifornia Northstate College Of Pharmacy, Llc Novel formulations and uses for Turmeric extracts
CN105056157A (en) * 2015-09-22 2015-11-18 郭新奎 Composition for treating acute pancreatitis and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6444583B2 (en) * 2013-03-22 2018-12-26 小林製薬株式会社 Oral composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0965864A (en) * 1995-08-30 1997-03-11 Riken Vitamin Co Ltd Antioxidant preparation for food
JPH09143086A (en) * 1995-11-22 1997-06-03 San Eng:Kk Drug and cosmetic for treatment of skin disease
JPH10179086A (en) * 1996-11-05 1998-07-07 Riken Vitamin Co Ltd Oil-solubilizing liquid containing plant sterol as well as drinks and their production
JP2001161306A (en) * 1999-12-03 2001-06-19 Ezaki Glico Co Ltd Method for producing gelatin capsule excellent in palatability
WO2002047699A1 (en) * 2000-12-12 2002-06-20 Kaneka Corporation Compositions for preventing or ameliorating multiple risk factor syndromes
JP2003137799A (en) * 2001-03-28 2003-05-14 Kiyotoshi Oshiro Diacylglycerol solution including turmeric and method for producing the same
WO2003084556A1 (en) * 2002-04-04 2003-10-16 Kaneka Corporation Process for producing fat composition containing hydrophobic components of glycyrrhiza

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0965864A (en) * 1995-08-30 1997-03-11 Riken Vitamin Co Ltd Antioxidant preparation for food
JPH09143086A (en) * 1995-11-22 1997-06-03 San Eng:Kk Drug and cosmetic for treatment of skin disease
JPH10179086A (en) * 1996-11-05 1998-07-07 Riken Vitamin Co Ltd Oil-solubilizing liquid containing plant sterol as well as drinks and their production
JP2001161306A (en) * 1999-12-03 2001-06-19 Ezaki Glico Co Ltd Method for producing gelatin capsule excellent in palatability
WO2002047699A1 (en) * 2000-12-12 2002-06-20 Kaneka Corporation Compositions for preventing or ameliorating multiple risk factor syndromes
JP2003137799A (en) * 2001-03-28 2003-05-14 Kiyotoshi Oshiro Diacylglycerol solution including turmeric and method for producing the same
WO2003084556A1 (en) * 2002-04-04 2003-10-16 Kaneka Corporation Process for producing fat composition containing hydrophobic components of glycyrrhiza

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010043032A (en) * 2008-08-13 2010-02-25 Fuji Chem Ind Co Ltd High concentration astaxanthin extract
EP2410874A1 (en) * 2009-03-26 2012-02-01 Abbott Laboratories Nutritional composition comprising curcuminoids and methods of manufacture
JP2012521431A (en) * 2009-03-26 2012-09-13 アボット・ラボラトリーズ Nutritional composition containing curcuminoid and method for producing the same
JP2013202005A (en) * 2012-03-29 2013-10-07 National Agriculture & Food Research Organization Curcumin-containing oil and fat, and method for producing the same
JP2015527361A (en) * 2012-08-21 2015-09-17 カリフォルニア ノースステイト カレッジ オブ ファーマシー, エルエルシーCalifornia Northstate College Of Pharmacy, Llc Novel formulations and uses for Turmeric extracts
US10231940B2 (en) 2012-08-21 2019-03-19 California Northstate College Of Pharmacy, Llc Method of producing a safe, whole-extract of curcuma for oral and topical use
US10973778B2 (en) 2012-08-21 2021-04-13 California Northstate College Of Pharmacy, Llc Using edible carriers to produce Curcuma extracts for oral and topical use
CN105056157A (en) * 2015-09-22 2015-11-18 郭新奎 Composition for treating acute pancreatitis and preparation method thereof

Also Published As

Publication number Publication date
JPWO2005097152A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2005097152A1 (en) Turmeric extract-containing composition having improved caking capacity
KR100951758B1 (en) Fat Composition
JP7017043B2 (en) Powdered fats and oils, foods and drinks containing them
US20050129830A1 (en) Oil or fat composition
JP2007512407A (en) Oil composition rich in diglyceride of conjugated linoleic acid
JP5820256B2 (en) Self-emulsifying formulation
KR20170083048A (en) Powdered oil/fat, food/beverage including powdered oil/fat, and method for producing powdered oil/fat
JP5033553B2 (en) Emulsification stabilizer
US11839687B2 (en) Solid composition
JP2011012003A (en) Emulsion composition for soft capsule and soft capsule
JP2001040386A (en) Oil and fat composition
WO2009034124A1 (en) Omega-3 stabilisation towards oxidation
JP6694726B2 (en) O / D type emulsion composition, oil-in-water type emulsion composition, food and drink and food material
WO2006134970A1 (en) Coenzyme q10-containing water-soluble composition and process for production thereof
JP2016104003A (en) Acidic separation liquid-state seasoning
JP2013209493A (en) Powdery oil and fat, method for producing the same, powdery oil and fat-containing food, powdery oil and fat-containing oral medicinal product, and method for producing the powdery oil and fat-containing food
JPS61118318A (en) Composition having improving action on serum lipid
CN109475141A (en) Oily admixture and preparation method
JP6843376B2 (en) Capsule coating composition and capsule
JP4268473B2 (en) Oil composition
CA2551119C (en) Lipase inhibitor
Hassim et al. Characteristics of sunflower wax, carnauba wax and beeswax in palm Superolein blended oil
EP3000328B1 (en) Fat composition
JPS61118323A (en) Composition having improving action on serum lipid
JP5283654B2 (en) Filling composition for soft capsules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006511991

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase